EGFR and esophageal squamous cell carcinoma: In addition, gefitinib, a low molecular weight EGFR inhibitor, did not improve overall survival in unselected patients with EC, including ESCC, but provided a palliative effect in a subgroup of difficult-to-treat patients with short life expectancy [43].